Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The objective of the clinical study of the medicinal product for medical use: to compare
efficacy and safety of the generic drug BCD-063 and Copaxone®-Teva in patients with
relapsing-remitting multiple sclerosis.
Period of the clinical study of the medicinal product for medical use: from June 10, 2013 to
March 23, 2016.
Number of patients, involved into the study of the medicinal product for medical use: 158
patients.